Gunnar Kaufmann - Oncternal Therapeutics Chief Officer
| ONCT Stock | USD 0.75 0.04 5.63% |
Insider
Gunnar Kaufmann is Chief Officer of Oncternal Therapeutics
| Age | 48 |
| Address | 12230 El Camino Real, San Diego, CA, United States, 92130 |
| Phone | 858 434 1113 |
| Web | https://www.oncternal.com |
Oncternal Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.7645) % which means that it has lost $0.7645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4986) %, meaning that it created substantial loss on money invested by shareholders. Oncternal Therapeutics' management efficiency ratios could be used to measure how well Oncternal Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.13 in 2024. Return On Capital Employed is likely to drop to -1.39 in 2024. Change To Liabilities is likely to gain to about 2.1 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 31.8 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jesse Shefferman | Protara Therapeutics | 52 | |
| Dr IV | Assembly Biosciences | 52 | |
| AO FRACP | Assembly Biosciences | 65 | |
| MBA MPH | Protara Therapeutics | 41 | |
| MD BA | Pasithea Therapeutics Corp | 76 | |
| Robert Bazemore | Nuvation Bio | 53 | |
| Kim Blickenstaff | Nuvation Bio | 68 | |
| Gary Hattersley | Nuvation Bio | 57 | |
| Elizabeth Nguyen | Surrozen | N/A | |
| Sarah JD | Absci Corp | 45 | |
| Kathryn Falberg | Nuvation Bio | 60 | |
| Timothy Moore | Instil Bio | 63 | |
| Steven Martin | Armata Pharmaceuticals | 63 | |
| MSc MBA | Passage Bio | 55 | |
| Mark MD | Passage Bio | 60 | |
| Hannah Fry | Protara Therapeutics | 33 | |
| W Vernon | Nuvation Bio | 65 | |
| Simona King | Passage Bio | 52 | |
| Noreen MD | Kezar Life Sciences | 59 | |
| Daniel Schneiderman | Pasithea Therapeutics Corp | 46 | |
| Kerry Wentworth | Nuvation Bio | 51 | |
Management Performance
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.76 |
Oncternal Therapeutics Leadership Team
Elected by the shareholders, the Oncternal Therapeutics' board of directors comprises two types of representatives: Oncternal Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oncternal. The board's role is to monitor Oncternal Therapeutics' management team and ensure that shareholders' interests are well served. Oncternal Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oncternal Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pablo Urbaneja, Senior Development | ||
| Anita Wiseth, Senior Resources | ||
| Gunnar Kaufmann, Chief Officer | ||
| Chase JD, General Secretary | ||
| Salim MD, Chief Officer | ||
| Chase Leavitt, General Secretary | ||
| Steven Hamburger, VP Assurance | ||
| Richard CPA, Treasurer CFO | ||
| Rajesh Krishnan, Chief Officer |
Oncternal Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Oncternal Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.76 | ||||
| Operating Margin | (17.57) % | ||||
| Current Valuation | (12.17 M) | ||||
| Shares Outstanding | 2.96 M | ||||
| Shares Owned By Insiders | 9.23 % | ||||
| Shares Owned By Institutions | 12.07 % | ||||
| Number Of Shares Shorted | 14.21 K | ||||
| Price To Earning | (37.77) X | ||||
| Price To Book | 0.24 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Oncternal Stock Analysis
When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.